Changchun Hi-Tech said in an institutional conference call on August 20 that Baike Biotech has built multiple R&D technology platforms, including an mRNA vaccine technology platform, and continues to promote the expansion and application of mRNA platform technology. As of the end of June 2026, Baike Biotech's HSV-2 vaccine is undergoing phase I clinical trials; the generic tumor mRNA vaccine developed by Baike Biotech's shareholding company Chuanxin Biomedical Co., Ltd. is undergoing IIT clinical trials at Peking Union Medical College Hospital.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.